Additional resources

Vizient Pharmacy program members can access supporting resources including price change projections at the individual medication level

Not already enjoying Vizient Pharmacy program benefits?

Learn more now


Projected overall drug price inflation rate for Jan. 1 – Dec. 31, 2023

Expert insights

Find out more inside

  • 5

    Top drugs by Vizient member spend: Adalimumab, Remdesivir, Pembrolizumab, Ustekinumab, Ocrelizumab

  • 7

    Biosimilar competition for Humira (adalimumab) is coming – seven approved, more on the way

  • 20%

    Site of care is expected to shift toward the home with a 20% increase in volume by 2032

  • 24%

    The cardiology outpatient service line is expected to have 24% growth in utilization over the next 10 years

  • 55%

    Specialty medications continue to be the largest area of drug expenditures at 55% of total member spend

  • 3.29%

    Pediatric pharmaceutical costs are rising with a projected inflation rate of 3.29%

There is no limit to the challenges and opportunities facing pharmacy practice over the next six to 18 months.

Steven Lucio, PharmD, BCPS

Sr. Principal, Vizient Center for Pharmacy Practice Excellence